DESIGNATED COMPOUNDS Sample Clauses

DESIGNATED COMPOUNDS. In the event that Licensee determines to cease the development of a Designated Compound prior to obtaining Regulatory Approval therefor, Licensee shall have the right to substitute another Licensed Compound for such Designated Compound upon written notice to Licensor (which written notice will identify both the “new” Designated Compound and the Designated Compound that is being “deselected”); provided that, at no time will there be more than [**] Designated Compounds.
Sample 1Sample 2
AutoNDA by SimpleDocs
DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Primary Active Compounds Report for a Target by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A, CUSTOMER shall notify NeoGenesis whether it will classify any Primary Active Compounds as a Selected Compound for further study or optimization. If CUSTOMER does not identify any Selected Compound(s) within such period, the license granted CUSTOMER under Section 3.1 shall terminate with respect to the applicable Target and be of no further force or effect with respect to such Target, and no further payment from CUSTOMER shall be due with respect to such Target.
Sample 1
DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Final Target Report for each Target by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A, Mitsubishi shall notify NeoGenesis whether it will classify any Candidate Compound C (or any derivative compound(s) of such Candidate Compound C) as candidates for drug development based on Mitsubishi's good faith evaluation of the satisfaction of the Success Criteria by such Candidate Compound C (or any derivative compound(s) of such Candidate Compound C) (each, a DESIGNATED COMPOUND). Mitsubishi may select [*] Designated Compounds for each Target. If Mitsubishi does not identify any Designated Compound(s) within such period, then upon [*] notice from NeoGenesis and unless Mitsubishi identifies *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. such Designated Compound(s) within such [*] period, the license granted Mitsubishi shall terminate and be of no further force or effect with respect to the applicable Target, and no further payment from Mitsubishi shall be due with respect to such Target.
Sample 1
DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Selected Compounds for each Target by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A (or the delivery of the corresponding notice regarding Primary Compound Activity by OGS in accordance with ATTACHMENT A), OGS shall notify NeoGenesis whether it will classify any Selected Compounds (or any derivative compound(s) of such Selected Compounds) as the basis for optimisation so as to yield a candidate for drug development based on OGS's good faith evaluation of * = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. the satisfaction of the Success Criteria by such Selected Compound (or any derivative compound(s) of such Selected Compounds) (each, a DESIGNATED COMPOUND). If OGS does not identify any Designated Compound(s) within such period, the license granted OGS shall terminate and be of no further force or effect with respect to the applicable Target, and no further payment from OGS shall be due with respect to such Target.
Sample 1
DESIGNATED COMPOUNDS. (a) Within one hundred twenty (120) days following the delivery of the Selected Compounds for each Target by NeoGenesis in accordance with Section 2.4 and Attachment A (or the delivery of the corresponding notice regarding Primary Compound Activity by OGS in accordance with Attachment A), OGS shall notify NeoGenesis whether it will classify any Selected Compounds (or any derivative compound(s) of such Selected Compounds) as the basis for optimisation so as to yield a candidate for drug development based on OGS’s good faith evaluation of the satisfaction of, the Success Criteria by such Selected Compound (or any derivative compound(s) of such Selected Compounds) (each, a Designated Compound). If OGS does not identify any Designated Compound(s) Within such period, the license granted OGS shall terminate and be of no further force or effect with respect to the applicable Target, and no further payment from OGS shall be due with respect to such Target.
Sample 1

Related to DESIGNATED COMPOUNDS

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Combination Product The term “

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Joint Manufacturing Committee A joint manufacturing committee (the “Joint Manufacturing Committee” or “JMC”) will be established pursuant to the Supply Agreement. The roles and responsibilities of the JMC shall be as specified in the Supply Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.